Browsing by Author "Jin, R."
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
Item ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS (R)), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone(Wiley, 2004-10) Piratvisuth, T.; Marcellin, P.; Lau, G.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Lu, Z.M.; Germanidis, G.; Yurdaydın, C.; Diago, M.; Lai, M.Y.; Button, P.; Why, R.D.; Pluck, N.; Gürel, S.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.Bu çalışma, 29 Ekim- 02 Kasım 2004 tarihleri arasında Boston[Amerika Birleşik Devletleri]’nde düzenlenen 55. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)’da bildiri olarak sunulmuştur.Item First detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B: Data from a multicenter, randomized, partially double-blind study of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine alone(Wiley, 2004-10) Bonino, F.; Lau, G.; Macellin, P.; Hadziyannis, S.; Kitis, G.; Jin, R.; Yao, G.B.; Piratvisuth, T.; Germanidis, G.; Yurdaydın, Cihan; Diago, M.; Lai, M.; McCloud, P.; Brunetto, M.R.; Farci, P.; Gürel, Selim; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Bilim Dalı.Item The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment(Elsevier, 2006) Marcellin, Patrick; Bonino, Ferruccio; Lau, George; Farci, Patrizia; Yurdaydin, C.; Piratvisuth, Teerha; Jin, R.; Hadziyannis, Stephanos J.; Lu, Zhimeng; Popescu, Madalina; Gürel, Selim; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Gastroenteroloji Bilim Dalı.Item Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B(Massachusetts Medical Soc, 2004-09-16) Marcellin, Patrick; Lau, George; Bonino, Ferruccio; Farci, Patrizia; Hadziyannis, Stephanos; Jin, R.; Lu, ZM; Piratvisuth, Teerha; Germanidis, Georgios; Yurtaydin, Cihan; Moises, Diago; Mingyang, Lai; Button, P.; Pluck, Nigel; Gurel, Selim; Bursa Uludağ Üniversitesi/Tıp Fakültesi.Background: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications. Methods: We compared the efficacy and safety of peginterferon alfa-2a (180 microg once weekly) plus placebo, peginterferon alfa-2a plus lamivudine (100 mg daily), and lamivudine alone in 177, 179, and 181 patients with HBeAg-negative chronic hepatitis B, respectively. Patients were treated for 48 weeks and followed for an additional 24 weeks. Results: After 24 weeks of follow-up, the percentage of patients with normalization of alanine aminotransferase levels or hepatitis B virus (HBV) DNA levels below 20,000 copies per milliliter was significantly higher with peginterferon alfa-2a monotherapy (59 percent and 43 percent, respectively) and peginterferon alfa-2a plus lamivudine (60 percent and 44 percent) than with lamivudine monotherapy (44 percent, P=0.004 and P=0.003, respectively; and 29 percent, P=0.007 and P=0.003, respectively). Rates of sustained suppression of HBV DNA to below 400 copies per milliliter were 19 percent with peginterferon alfa-2a monotherapy, 20 percent with combination therapy, and 7 percent with lamivudine alone (P<0.001 for both comparisons with lamivudine alone). Loss of hepatitis B surface antigen occurred in 12 patients in the peginterferon groups, as compared with 0 patients in the group given lamivudine alone. Adverse events, including pyrexia, fatigue, myalgia, and headache, were less frequent with lamivudine monotherapy than with peginterferon alfa-2a monotherapy or combination therapy. Conclusions: Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of response, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a than with lamivudine. The addition of lamivudine to peginterferon alfa-2a did not improve post-therapy response rates.Item A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.(Wiley, 2003-10) Marcellin, P.; Lau, G.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Lu, Z.; Piratvisuth, T.; Germanidis, G.; Yurdaydın, C.; Diago, M.; Lai, M.; Button, P.; Pluck, N.; Gürel, S.; Uludağ Üniversitesi/Tıp Fakültesi.; AAH-5364-2019; ABI-3764-2020Item Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone(Wiley, 2004-10) Germanidis, G.; Marcellin, P.; Lau, G.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Yao, G.B.; Piratvisuth, T.; Yurdaydın, C.; Diago, M.; Lai, M.Y.; Popescu, M.; Pluck, N.; Gürel, S.; Uludağ Üniversitesi/Tıp Fakültesi.